Lip (2017) | Cohort (n = 14,020) | NOACs (apixaban, rivaroxaban, dabigatran) vs warfarin | 66.5 (61.1 - 70.4) | No significant difference in stroke prevention. Bleeding events were significantly lower for treatment with apixaban ([HR], 0.35; 95% CI, 0.17 - 0.72) and dabigatran (HR, 0.48; 95% CI, 0.30 - 0.77) vs. warfarin. Bleeding event was not significantly different for treatment with rivaroxabanvs warfarin (HR, 0.84; 95% CI, 0.49 - 1.44). |